BR9815966A - Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante - Google Patents

Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante

Info

Publication number
BR9815966A
BR9815966A BR9815966-6A BR9815966A BR9815966A BR 9815966 A BR9815966 A BR 9815966A BR 9815966 A BR9815966 A BR 9815966A BR 9815966 A BR9815966 A BR 9815966A
Authority
BR
Brazil
Prior art keywords
beta
ifn
recombinant interferon
interferon beta
human
Prior art date
Application number
BR9815966-6A
Other languages
English (en)
Inventor
John Alam
Mark Rogge
Susan Goelz
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9815966A publication Critical patent/BR9815966A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçãO HUMANO DE INTERFERON BETA-1a (IFN-BETA-1a) RECOMBINANTE"<D>. Composições líquidas compreendendo MU tampão de pH de cerca de 7,2 interferon beta recombinante e 15 mg/ml de albumina de soro humano, e kits para administração parenteral das referidas composições.
BR9815966-6A 1998-05-29 1998-05-29 Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante BR9815966A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/007242 WO1999062542A1 (en) 1998-05-29 1998-05-29 Recombinant human interferon beta-1a (ifn-beta-1a) formulation

Publications (1)

Publication Number Publication Date
BR9815966A true BR9815966A (pt) 2001-02-28

Family

ID=22266817

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815966-6A BR9815966A (pt) 1998-05-29 1998-05-29 Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante

Country Status (16)

Country Link
EP (1) EP1082132A1 (pt)
JP (1) JP2002516874A (pt)
KR (1) KR20010052454A (pt)
CN (1) CN1299285A (pt)
AU (1) AU8822598A (pt)
BR (1) BR9815966A (pt)
CA (1) CA2333063A1 (pt)
EA (1) EA200001252A1 (pt)
EE (1) EE200000694A (pt)
HU (1) HUP0102241A2 (pt)
IL (1) IL139933A0 (pt)
IS (1) IS5732A (pt)
NO (1) NO20006022L (pt)
SK (1) SK17762000A3 (pt)
TR (1) TR200003521T2 (pt)
WO (1) WO1999062542A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
ES2291274T3 (es) * 2000-12-21 2008-03-01 Resuscitation Technologies, Llc Composiciones de t3 estable y metodos de uso de las mismas.
CN1325651C (zh) * 2001-05-24 2007-07-11 大连金威基因技术有限公司 人重组乙型干扰素的高效表达及其应用
CN1535724B (zh) * 2003-04-23 2012-09-05 北京金迪克生物技术研究所 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
CA2707484C (en) * 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
EP4211154A1 (en) * 2020-09-12 2023-07-19 Academia Sinica Re-folded human serum albumin and use thereof for anti-tumor

Also Published As

Publication number Publication date
EA200001252A1 (ru) 2001-06-25
AU8822598A (en) 1999-12-20
SK17762000A3 (sk) 2001-07-10
NO20006022D0 (no) 2000-11-28
CN1299285A (zh) 2001-06-13
NO20006022L (no) 2001-01-26
WO1999062542A1 (en) 1999-12-09
HUP0102241A2 (hu) 2001-10-28
CA2333063A1 (en) 1999-12-09
IS5732A (is) 2000-11-24
EE200000694A (et) 2002-06-17
TR200003521T2 (tr) 2001-07-23
KR20010052454A (ko) 2001-06-25
JP2002516874A (ja) 2002-06-11
EP1082132A1 (en) 2001-03-14
IL139933A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
BR9814880A (pt) HormÈnios de glicoproteìna bifuncionais de cadeia única
BR9915548A (pt) Proteìnas de fusão de interferon-beta e usos
ATE274917T1 (de) Flüssige interferon-beta formulierungen
BR9814276A (pt) Antìgenos de superfìcie
FI974429A (fi) Suspendoituja peptidi/proteiinivalmisteita
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
EA200501699A1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин
FR06C0032I2 (fr) Formulations proteiniques
BR9809951A (pt) Método para tratamento da obesidade
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
ATE213940T1 (de) Parenteral anzuwendende arzneizubereitung enthaltend amiodaron
DE69940635D1 (de) Copolymer-zusammensetzungen zur oralen verabreichung
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita&#39; citotossica
EE05213B1 (et) Lmfotoksiin- β retseptori (LT- β-R) blokeeriva agensi kasutamine ja LT- β-R-i blokeerivat agensit ning CD40L-i blokeerivat agensit sisaldav farmatseutiline kompositsioon
BR9815966A (pt) Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante
Chadha et al. Interferons and interferon inhibitory activity in disease and therapy
UY27373A1 (es) Formulaciones de interferón beta-humano
BR9714376A (pt) Antagonistas de somatostatina
BR0212287A (pt) Proteìna de ligação caspase-8, sua preparação e uso
MY118946A (en) Novel intermediates and their use to prepare n, n&#39;&#39;- bridged bisindolylmaleimides
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
PT1105503E (pt) Guanililciclase humana soluvel alfal/betal (hsgc alfal/betal) isolada e purificada

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5,6,7,8 E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.